[A15-60] Sacubitril/valsartan - Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2016
Project no.:
A15-60
Commission:
Commission awarded on 23.12.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-29 | Sacubitril/valsartan - Addendum to Commission A15-60 | Commission completed |
| A23-56 | Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2016-06-16 A G-BA decision was published.